Skip to main content
Canada’s most-awarded newsroom for a reason
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
Canada’s most-awarded newsroom for a reason
$1.99
per week
for 24 weeks
Start Today
// //
Subscribe from $1.99/WK
Register
AdChoices

Abiomed Inc NASDAQ: ABMD-Q

Today's Change
Volume
Real-Time Last Update Last Sale Cboe BZX Real-Time
Alerts Watchlist Portfolio

Today's Trading

Day Low 350.32
Day High 353.79
Open:351.55
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Latest
number cruncher
These 11 growing companies from the S&P 500 are becoming increasingly attractive
Subscriber content
investment ideas
Big Tech drives S&P 500 to record high in coronavirus rally
number cruncher
Ten U.S. stocks with the financial flexibility to withstand a second downturn
Subscriber content
number cruncher
Twelve quality U.S. health care stocks for market uncertainty
Subscriber content
number cruncher
Ten solid, growth-oriented U.S. health-care stocks
Subscriber content
investment ideas
Another medtech stock has quietly slipped into lead in S&P 500
Description
Abiomed, Inc. is a provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients. The Company develops, manufactures and markets proprietary products that are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company'sproducts are used in the cardiac catheterization lab, or cath lab, by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures.

Fundamentals

Market Capitalization, $K
Shares Outstanding, K
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

View Earnings zacks

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.

Moderate Buy
View Estimates zacks

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

Download Premium PDF Refinitiv. Trademark. Data is Just the Beginning.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

Download Premium PDF StockCalc

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Download Free PDF ValueEngine logo

Latest Press Releases

More Stories
FDA Grants Breakthrough Device Designation to Impella ECP, the World's Smallest Heart Pump
- Business Wire - Wed Aug 18, 7:02AM CDT
Business Wire - CMTX
Wed Aug 18, 7:02AM CDT
The United States Food and Drug Administration (FDA) has granted breakthrough device designation to Abiomed's (NASDAQ: ABMD) Impella ECP expandable percutaneous heart pump. The designation means the FDA will prioritize Impella ECP's regulatory review processes including design iterations, clinical study protocols and pre-market approval (PMA) application.
Abiomed Announces Record Revenue of $253 Million, Up 53% Year Over Year
- Business Wire - Wed Aug 4, 3:15PM CDT
Business Wire - CMTX
Wed Aug 4, 3:15PM CDT
Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced financial results for the quarter ended June 30, 2021.
Abiomed First Quarter Fiscal 2022 Earnings and Conference Call Notification
- Business Wire - Thu Jul 15, 6:00AM CDT
Business Wire - CMTX
Thu Jul 15, 6:00AM CDT
Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, August 5, 2021, the Company will release financial results for the first quarter of the fiscal year 2022. The Company will host a conference call to discuss the results on Thursday, August 5, 2021 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Financial Officer, will host the conference call.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 342.58 +2.34% increase
on 09/22/21
Period Open:351.81
Price movement based on the high, low and last over the given period.
376.99 -7.00% decrease
on 09/07/21
 -1.20 (-0.34%) decrease
since 08/23/21
3-Month 305.76 +14.67% increase
on 07/15/21
Period Open:321.70
Price movement based on the high, low and last over the given period.
376.99 -7.00% decrease
on 09/07/21
 +28.91 (+8.99%) increase
since 06/23/21
52-Week 242.73 +44.44% increase
on 10/30/20
Period Open:260.11
Price movement based on the high, low and last over the given period.
387.40 -9.50% decrease
on 01/28/21
 +90.50 (+34.79%) increase
since 09/23/20

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

© 2021 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies